Roche’s New Leukemia Drug Promising, Hematologists Say as They Await More Data
by Elizabeth Krutoholow
As Roche’s top-selling leukemia treatment Rituxan nears its patent expiration, the drug maker is pushing to see its newer product, GA101, step into the spotlight. Approved by the FDA on Friday, GA101, also known as obinutuzumab, is a major part of Roche’s strategy to defend its franchise from biosimilar products. An embargo on the data from the late-stage trial that culminated in the new drug’s recent approval will be lifted Nov. 7, with full information slated for release at the American Society of Hematology (ASH) Annual Meeting in December, giving clinicians and investors alike more information on GA101’s performance relative to its soon-to-be-generic predecessor.